SCHEMBL21603837

SCHEMBL21603837

CC(C)(C)OC(=O)NC1CCCc2c1sc(NC(=O)C1CC1)c2C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
FLT3 P36888 1/20 0.41
CNR2 P34972 2/20 0.37
CNR1 P21554 1/20 0.37
BTK Q06187 1/20 0.36
REV1 Q9UBZ9 1/20 0.36
ALDH1A1 P00352 5/20 0.35
GAA P10253 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRIN2C Q14957 2/20 0.35
MEN1 O00255 1/20 0.35
MITF O75030 1/20 0.35
KMT2A Q03164 1/20 0.35
KLF5 Q13887 1/20 0.35
HPGD P15428 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597795 0.87 ALDH1A1 (0.49) MAPTKDM4EHSD17B10ALDH1A1GAA
SCHEMBL21603786 0.86 CNR2 (0.43) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21604238 0.84 CNR2 (0.46) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597616 0.78 KDM4E (0.47) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597712 0.78 KDM4E (0.47) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21603874 0.77 KDM4E (0.50) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL27418748 0.74 KDM4E (0.46) MAPTKDM4EHSD17B10FLT3CNR2
Water SCHEMBL21597714 0.74 KDM4E (0.47) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597670 0.72 MAPT (0.47) MAPTKDM4EHSD17B10FLT3CNR2
SCHEMBL21597636 0.72 MAPT (0.41) MAPTKDM4EHSD17B10FLT3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885KDM4E 3965/4885HSD17B10 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.